Arbutus Biopharma Corp
Company Profile
Business description
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Contact
701 Veterans Circle
WarminsterPA18974
USAT: +1 267 469-0914
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
19
Stocks News & Analysis
stocks
Updating our assumed commodity prices and fair values of the two largest Aussie miners
stocks
Do AI labs like Anthropic and OpenAI have economic moats?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,921.50 | 15.50 | -0.17% |
| CAC 40 | 7,834.14 | 1.26 | 0.02% |
| DAX 40 | 25,302.29 | 24.61 | 0.10% |
| Dow JONES (US) | 51,850.55 | 195.60 | 0.38% |
| FTSE 100 | 10,713.95 | 57.67 | 0.54% |
| HKSE | 24,345.22 | 74.02 | 0.30% |
| NASDAQ | 27,245.90 | 120.27 | -0.44% |
| Nikkei 225 | 67,777.52 | 1,253.40 | -1.82% |
| NZX 50 Index | 13,749.60 | 78.02 | -0.56% |
| S&P 500 | 7,807.24 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,783.90 | 0.70 | 0.01% |
| SSE Composite Index | 3,800.86 | 3.62 | 0.10% |